Description
The SimpleChIP
® Plus Sonication Chromatin IP Kit is a complete ChIP kit. It contains the buffers and reagents necessary to perform up to 24 chromatin immunoprecipitations from cells or tissue samples, and is optimized for 4 X 10
6 cells or 25 mg of tissue per immunoprecipitation. A complete assay can be performed in as little as two days and can easily be scaled up or down for use with more or less cells or tissue sample. This kit is compatible with both ChIP-qPCR and ChIP-seqCells or tissue are fixed with formaldehyde and lysed, and chromatin is fragmented by sonication to obtain chromatin fragments ranging from 200 to 1000 bp. Sonication-based fragmentation is the more traditional method for fragmenting chromatin; however, sonication should be optimized such that the desired fragment size is achieved with the minimal amount of sonication required, as over-sonication can result in a decrease in immunoprecipitation, specifically for transcription factors and cofactors. The cell and nuclear lysis buffers for this kit have been optimized to maximize enrichment of histones, transcription factors and cofactors. Chromatin immunoprecipitations are performed using ChIP-validated antibodies and ChIP-Grade Protein G Magnetic Beads. After reversal of protein-DNA cross-links, the DNA is purified using DNA purification spin columns, allowing for easy and efficient recovery of DNA and removal of protein contaminants without the need for phenol/chloroform extractions and ethanol precipitations. The enrichment of particular DNA sequences during immunoprecipitation can be analyzed by a variety of methods, including standard PCR, quantitative real-time PCR, or amplification for ChIP on chip, sequencing or cloning techniquesThe SimpleChIP
® Plus Kit also provides important controls to ensure a successful ChIP experiment. The
Background
The chromatin immunoprecipitation assay is a powerful and versatile technique used for probing protein-DNA interactions within the natural chromatin context of the cell. This assay can be used to identify multiple proteins associated with a specific region of the genome, or the opposite, to identify the many regions of the genome bound by a particular protein. It can be used to determine the specific order of recruitment of various proteins to a gene promoter or to "measure" the relative amount of a particular histone modification across an entire gene locus. In addition to histone proteins, the ChIP assay can be used to analyze binding of transcription factors and co-factors, DNA replication factors and DNA repair proteins. When performing the ChIP assay, cells or tissues are first fixed with formaldehyde, a reversible protein-DNA cross-linking agent that "preserves" the protein-DNA interactions occurring in the cell. Cells are lysed and chromatin is harvested and fragmented using either sonication or enzymatic digestion. The chromatin is then immunoprecipitated with antibodies specific to a particular protein or histone modification. Any DNA sequences that are associated with the protein or histone modification of interest will co-precipitate as part of the cross-linked chromatin complex and the relative amount of that DNA sequence will be enriched by the immunoselection process. After immunoprecipitation, the protein-DNA cross-links are reversed and the DNA is purified. Standard PCR or Quantitative Real-Time PCR can be used to measure the amount of enrichment of a particular DNA sequence by a protein-specific immunoprecipitation. Alternatively, the ChIP assay can be combined with genomic tiling micro-array techniques, high throughput sequencing, or cloning strategies, all of which allow for genome-wide analysis of protein-DNA interactions and histone modifications.
References
[1] Orlando, V. (2000) Trends Biochem Sci 25, 99-104.
[2] Liu, Q. et al. (2000) Genes Dev 14, 1448-59.
[3] Kuo, M.H. and Allis, C.D. (1999) Methods 19, 425-33.
[4] Zhao, H. and Piwnica-Worms, H. (2001) Mol Cell Biol 21, 4129-39.
[5] Agalioti, T. et al. (2000) Cell 103, 667-78.
[6] Jiang, K. et al. (2003) J Biol Chem 278, 25207-17.
[7] Soutoglou, E. and Talianidis, I. (2002) Science 295, 1901-4.
[8] Martin, S.A. and Ouchi, T. (2008) Mol Cancer Ther 7, 2509-16.
[9] Mikkelsen, T.S. et al. (2007) Nature 448, 553-60.
[10] Chen, M.S. et al. (2003) Mol Cell Biol 23, 7488-97.